Kornimate/medical-research-clean huggingface dataset:
ocs-01 in treating inflammation and pain in post-cataract patients

Conditions: Inflammation Corneal; Pain, Postoperative

Summary: the dx-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of ocs-01 compared to vehicle in the treatment of inflammation and pain following cataract surgery. the primary objective is to evaluate the efficacy and safety of ocs-01 compared to placebo and the secondary objective is to evaluate the optimal dosing frequency (once a day \[qd\] or twice a day \[bid\]).

this is a multi-center, randomized, double-masked, placebo (vehicle)-controlled study, designed to evaluate the efficacy and safety of ocs-01 ophthalmic suspension (qd versus bid) compared to placebo in treating inflammation and pain following cataract surgery. subjects will be randomized 1:1:1 to receive ocs-01 qd, ocs-01 bid, or placebo bid. subjects will dose 1 drop in the study eye bid for 14 days, beginning 1 day post-surgery in the operated eye. the study will last up to 24 days, including a follow-up visit at visit 7 (day 22 ± 2).

Eligibility criteria:
inclusion criteria: 1. provide written informed consent, approved by the appropriate ethics committee; 2. be able to comply with the study requirements and visit schedule; 3. be at least 18 years of age of either sex or any race; 4. be planning to undergo unilateral cataract extraction via phacoemulsification and pciol implantation in the study eye; 5. have an anterior chamber cell score ≥ 2 at visit 2 (day 1 \[18 to 30 hours post-uncomplicated cataract surgery without vitreous loss\]); 6. have a pin-hole visual acuity (va) without any other correction \> 20 letters (approximately 20/400) in the operative eye and \> 35 letters (approximately 20/200) in the fellow eye as measured using an early treatment for diabetic retinopathy study (etdrs) chart at visit 1 (day -1 to day -28 \[prior to surgery\]); 7. have a negative urine pregnancy test at visit 1 (day -1 to day -28 \[prior to surgery\]), exclusion criteria: 1. have a known sensitivity or allergy to dexamethasone, corticosteroids, or any of the study medication's components; 2. be monocular; 3. have any intraocular inflammation (e.g. white blood cells or flare) present in either eye at the visit 1 (day -1 to day -28 \[prior to surgery\]) slit lamp examination; 4. have a score \> 0 on the ocular pain assessment at visit 1 (day -1 to day -28 \[prior to surgery\]) in the study eye; 5. use anti-inflammatory agents, analgesics/pain relievers (including opioids, narcotics, and other pain medications), or immunomodulating agents, systemically or in either eye, and/or use medications for benign prostatic hyperplasia (bph), from the washout period through the duration of the study.

Keywords: post-cataract, inflammation pain post-surgery corticosteroid anterior chamber cells flares
scleroligation for eradication of gastroesophageal varices.

Conditions: Gastroesophageal Varices

Summary: gastric varices occur in 5-33% of patients with portal hypertension. concomitant gastro esophageal varices are the most common type. both endoscopic sclerotherapy and band ligation are very effective in controlling acute esophageal varices bleeding and preventing rebleeding.

evaluation of a new scleroligation technique for management of bleeding gastro-esophageal varices regarding efficacy, complications, variceal recurrence, and survival.

Eligibility criteria:
inclusion criteria: * cirrhotic patients presenting with an acute or recent episode of gastro-esophageal variceal bleeding. exclusion criteria: * patients were excluded if they had malignancy of any origin. * any terminal illness, such as heart failure, uremia, or chronic pulmonary diseases. * other potential causes of git bleeding. * patients with previous endoscopic or surgical intervention for varices were also excluded.
sex-informed data in the covid-19 pandemic.

Conditions: Covid19

Summary: sex and gender matter to health equity, especially in a pandemic. sex (a biological attribute) and gender (a social construct) may influence an individual's susceptibility, vulnerability and exposure to infectious disease. in previous coronavirus epidemics (sars and mers), male sex was associated with worse outcomes. both immune and the hemostatic response display ample sexual dimorphism. the primary aim of the study is to determine whether sex differences in biomarkers of platelet and immune function, gut microbiome, clinical characteristics, therapy, clinical cost sensitive outcomes (i.e. in-hospital transition of care, case severity, and mortality due to covid-19) exist in patients affected by covid-19.


Eligibility criteria:
inclusion criteria: * patients with laboratory confirmed sars-cov-2 infection of any severity. exclusion criteria: * pregnancy. * younger than 18 years of age.

Keywords: sex gender thrombosis immunity gut microbiota
use of minocicline in patients with stroke

Conditions: Stroke; Brain Ischemia; Paralysis

Summary: the investigators will evaluate the national institute of health stroke scale/score (nihss)in patients with stroke, and then give minocycline 100mg po every 12 hours or placebo for five days, then perform periodic evaluations to determine the status and degree of neurological sequelae developed.


Eligibility criteria:
inclusion criteria: * nihss scale greater than 5 * onset of symptoms less than 24 hours * normal cranial tomography(ct) * ct evidence of cerebral ischemia * acceptance of study entry exclusion criteria: * hemorrhagic cerebrovascular disease * other neurological diseases * concomitant structural damage * history of neurosurgery * known allergy to tetracyclines * concomitant infectious diseases requiring antibiotic treatment. * history of stroke * women pregnant or breast-feeding

Keywords: stroke sequelaes minocicline
effects of adding triamcinolone acetonide to conbercept treatment for refractory diabetic macular edema (conte)

Conditions: Diabetes Mellitus, Type 2; Macular Edema

Summary: this study aimed to compare intravitreous conbercept alone with conbercept plus intravitreous triamcinolone acetonide in dme eyes which showed limited response to anti-vegf treatment after one injection.

some eyes with diabetic macular edema (dme) were not sensitive to anti-vascular endothelial growth factor (anti-vegf) therapy and required continuous injections. delayed control of macular edema might cause irreversible function loss. to predict the response to anti-vegf treatment according to the cst change after one injection was proved reasonable recently. adding intravitreous corticosteroids to the treatment regimen at early time might result in better outcomes than anti-vegf therapy alone. patients with diagnosis of refractory diabetic macular edema, confirmed by fluorangiography and optical coherence tomography (oct), with limited response to one intravitreal anti-vegf injection will be enrolled in the study. the enrolled patients will be randomized for the addition or not of the triamcinolone to intravitreal therapy.

Eligibility criteria:
inclusion criteria: * type ii diabetes * vison decrease was mainly caused by diabetic macular edema (dme) * bcva of 20/800 to 20/40 (decimal) * central subfield retinal thickness (cst) ≥ 300μm by optical coherence tomography (oct) in the study eye * pan-retinal photocoagulation finished at least 3 months ago, or no pan-retinal photocoagulation is expected in the next 6 months * within the last 3 months, one intravitreous injection of anti-vegf agent was performed, the cst reduction one month after injection was ≤ 20%. exclusion criteria: * non-dme related macular edema, or edema control would not benefit the vision (for example, macular atrophy) * exist of other reasons of macular edema, retinal vein occlusion, uveitis, iris rubeosis, high myopia * ocular media opacity of insufficient quality to obtain oct images and fundus images in the study eye * intraocular or periorbital injection of steroids within the last 3 months * macular grid photocoagulation within the last 4 months * history of vitrectomy * history of scleral buckle within the last 4 months, or intraocular surgery is expected in the next 6 months * any sign of ocular infection, including conjunctivitis, hordeolum, dacryocystitis * myocardial infarction, heart failure, stroke, or transient ischemic attack within one month * pregnant or breastfeeding women * uncontrolled hypertension, or blood pressure \>180/110 * patients with uncontrolled hyperglycemia, or hemoglobin a1c (hba1c) ≥10.0%, or under hemodialysis , or started insulin usage within the last 4 months, or expected to start insulin use for hyperglycemia control in the next 4 months * those cannot follow visits on time

Keywords: diabetic macular edema; conbercept; triamcinolone acetonide
international cancer of the head and neck, genetics and environment (interchange) study

Conditions: Evaluate the Association Between Certain Environmental Exposures (e.g. Cigarette Smoking, Alcohol Drinking, Betel Nut Chewing…) and Head and Neck Cancers; Assess the Effect of Genetic Factors, Including Both SNP and Copy Number Variation (CNV) Through Analysis of Both Main Effect and Gene-gene Interaction

Summary: our overall objective is to understand the role of lifestyle factors, genetics and hpv infection in the development and prognosis of head and neck cancer particularly in asia.


Eligibility criteria:
inclusion criteria: age 18\~80 incident head and neck cancer patients * oral, oropharynx and hypopharynx (c00-c14) * laryngreal cancer (c32) * \*esophageal cancer if possible (c15) exclusion criteria: * salivary gland (c07-c08) * nasopharynx (c11) * thyroid (c79.3)

Keywords: head and neck
topiramate for hospitalized patients with alcoholism: a 12-week study

Conditions: Alcohol Dependence

Summary: 12-week, open-label study of topiramate in hospitalized patients with alcoholism


Eligibility criteria:
inclusion criteria: * patients hospitalized due to alcohol-related problems * dsm-iv-tr alcohol dependence * \>/= 35 drinks/week (male) or \>/= 28 drinks/week (female) for \>/= 1 week during four weeks prior to the admission * audit score \>/= 8 * mild or no alcohol withdrawal * body mass index \> 18 kg/m2 * no pregnancy and no plan for pregnancy (female) * intention to decrease or stop drinking exclusion criteria: * severe psychiatric and cognitive disorders * other substance dependence, except nicotine and caffeine dependence, during 6 months prior to enrollment * taking antipsychotics, mood stabilizers, anticonvulsants, opioid analgesics, systematic steroids, carbonic anhydrase inhibitors, hydrochlorthiazide, metformin, pioglitazone, or disulfiram * moderate to high risk of suicide * medical history of narrow angle glaucoma, renal impairment, kidney stones, and seizures * unstable medical conditions * plan to receive a formal treatment for alcoholism from other treatment settings * under legal process * pregnancy and nursing woman * abnormal laboratory tests, including blood urea nitrogen, creatinine, electrolytes, and fasting blood sugar

Keywords: alcohol dependence alcoholism topiramate
a comparison of volatile anesthesia and total intravenous anesthesia (tiva)

Conditions: Rhinoplasty; Ecchymosis; Edema; Hemorrhage

Summary: in this study, investigators wanted to investigate the effect of volatile anesthesia and total intravenous anesthesia (tiva) on ecchymosis, edema, and intraoperative bleeding in rhinoplasty.

routine monitorization (blood pressure, pulse, oxygen saturation with pulse oximetry and electrocardiogram) will be applied to all patients taken into the operation room. in group p (tiva), induction of anesthesia will be achieved with 2 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 μ / kg fentanyl. propofol and remifentanil will be used in the continuation of anesthesia. in group s (volatile), anesthesia will be induced with 2 mg / kg propofol, 0.6 mg / kg rocuronium and 1 μ / kg fentanyl. 50% nitrous oxide + 50% oxygen and 2% sevoflurane will be used in the continuation of anesthesia. all patients will receive 2 ml/kg/hour ringer's lactate solution during the operation.

Eligibility criteria:
inclusion criteria: * between 18 and 65 years * planned to rhinoplasty * an american society of anesthesiologists score of 1 or 2 exclusion criteria: * steroid use * patients with coagulation disorders, •rejected to participation
study of the safety and efficacy of conivaptan (vaprisol®) to raise serum sodium levels in patients with severe traumatic brain injury

Conditions: Severe Traumatic Brain Injury

Summary: the investigators plan to utilize conivaptan (vaprisol) to promote isolated water loss, in combination with normal (physiologic) fluid replacement to maintain a normal blood volume status, in patients with severe tbi. the goal of this therapy is to raise blood sodium in a controlled fashion in subjects with severe tbi, and reduce the use of hypertonic saline infusion. we hypothesize that this therapy will maintain a stable state of high blood sodium, while decreasing the overall sodium load needed to achieve these goals.


Eligibility criteria:
inclusion criteria: * 18 years old or greater * initial diagnosis of an isolated, severe traumatic brain injury (glasgow coma score of 8 or less upon initial evaluation) * cerebral edema with a head ct and marshall classification of diffuse injury type ii, iii, or iv. * primary care team orders to raise blood sodium by 10 meq/l from baseline. * placement of an intraparenchymal fiberoptic monitor to monitor intracranial pressure (icp). exclusion criteria: * age \< 18 years * signs of hypovolemia including systolic bp \< 90 mmhg * signs of liver disease including jaundice and ascites * ast \> 35 units/l * alt \> 35 units/l * signs of renal disease including history of dialysis * serum creatinine \> 1.5 mg/dl * bun \> 20 mg/dl range * baseline serum sodium \>/= 145 meq/l * pregnant or lactating females * concomitant use of digoxin, ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, simvastatin and lovastatin * presentation to the tertiary care hospital \> 24 hours post-injury * multi-system traumatic injuries * diabetes insipidus * anticipation of diagnosis compatible with brain death, or no expectation of survival with 48 hours.

Keywords: traumatic brain injury conivaptan vaprisol sodium
exploration of therapeutic strategies for neoras wild-type metastatic colorectal cancer based on circulating tumor dna

Conditions: Colorectal Cancer Metastatic

Summary: following systemic therapy in metastatic colorectal cancer(mcrc),ras (including kras, nras and hras gene) status may change from a mutant(mt) to a wild-type(wt),a phenomenon known as "neoras wt"mcrc.neoras wt can be detected by longitudinal circulating tumor dna(ctdna) analysis.therefore, this prospective phase ii study was design to explore the detection rate of peripheral blood ctdna testing for neoras wt and its guiding value for subsequent treatment for mcrc.


Eligibility criteria:
inclusion criteria: 1. metastatic colorectal cancer with tissue ras mutation-type; 2. ecog (eastern cooperative oncology group) performance score is 0-1; 3. obtaining informed consent; 4. surgical specimens or punctured tissue specimens containing tumors can be obtained; 10ml of peripheral blood can be obtained exclusion criteria: 1. the pathology was not confirmed by colonoscopy biopsy or biopsy of metastasis; 2. colorectal cancer patients with clinical stage i-iii;patients with ras wild-type metastatic colorectal cancer confirmed by histological genetic testing;lack of adequate organ functions, such as severe abnormalities in blood, liver and kidney function
effects of antioxidants on cardiovascular risk measures (spice study)

Conditions: Cardiovascular; Psychological Stress

Summary: the purpose of this study is to assess whether feeding highly antioxidant spices of providing these same antioxidants as capsules is able to affect cardiovascular risk measures. because this is a new area of research, the investigators will use many measures to assess this question including blood markers, tests of blood vessel health, measures of blood pressure responses, measures of clotting activity, and other inflammation measures.


Eligibility criteria:
inclusion criteria: * age 30-65 * bmi 25-40 * non tobacco user * resting bp \< 160/100 * fasting glucose \< 126 mg/dl exclusion criteria: * tobacco use * use of female hormones * breastfeeding or planning to become pregnant during the study * use of lipid-lowering or blood pressure medications * chronic inflammatory disease or osteoarthritis requiring regular use of medication * chronic use of any form of anti-inflammatory or anti-psychotic drugs * use of daily aspirin or supplements (except stable dose of calcium) * history of heart attack or stroke, renal or hepatic disease, implanted medical devices, gastrointestinal disease * allergy or intolerance to any study foods * injury to fingers or arms that would interfere with vascular and blood pressure measurements * inability to comply with study protocol * allergy to adhesives or latex * aerobic exercise exceeding 2 hours per week

Keywords: spice responses to stress inflammatory
additional effects of steroid and dextrose to hyaluronic acid on knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: using double-blind, randomized controlled design to compare the immediate, short-term and intermediate-term additional therapeutic effects of ultrasound-guided corticosteroid injection and dextrose injection of hyaluronic acid injection on patients with knee osteoarthritis, under the basis of international classification of functioning, disability, and health.

a total of 60 patients will be collected. the participants will be randomized into two groups, including hyaluronic acid combined corticosteroid group and hyaluronic acid combined dextrose group. the balance, physical activity (10 meters normal and fast walk, up and downstairs, and 5 repeated chair-rising time, timed up and go test), functional performance and knee-related quality of life (western ontario and mcmaster universities osteoarthritis index、knee injury and osteoarthritis outcome score) will be evaluated. all the evaluations will be re-evaluated at one week after injection, one month after injection, three months after injection, and six months after injection. subjects and evaluators will be both blinded to the group's classification during the whole course of study.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of knee osteoarthritis can walk for 15 meters kellgren-lawerence grade 2 or greater than 2 can follow up for 6 months exclusion criteria: * major diseases will affect balance, such as stroke, infectious diseases, rheumatoid arthritis, dizziness, or vertigo fractures malignance pregnancy or prepare to pregnant received knee injections in the past 6 months previous operation of knee joints

Keywords: knee osteoarthritis, hyaluronic acid, steroid, dextrose
acute oral effects of heated tobacco products

Conditions: Nicotine Dependence, Cigarettes

Summary: heated tobacco products (htp) are devices which heat, but not burn tobacco. they do not produce cigarette smoke but rather an aerosol. htps are marketed as less harmful alternatives to smoking. use and awareness of these devices have grown exponentially in recent years, with probably millions of people currently using them. there is very little literature about them, so it is quite important to study the effects caused on the human body by these products. the benefits and risks of htp use are uncertain. there is no research on the acute oral effects of htps in the scientific literature.

measurements of acute oral effects before and after using htp with bland flavour (heets bronze selection), with methol flavour (heets blue selection), conventional cigarette and placebo device: measurement of exhaled co changes by smokerlyzer pico measurement of oral mucosal blood flow changes by perilam psi system high resolution (lasca method) measurement of blood pressure and pulse by an automatic blood pressure monitor (omron m2, omron healthcare inc., kyoto, japan)

Eligibility criteria:
inclusion criteria: * age: 18-49 years * signed consent form * smoking regularly heated tobacco product and/or conventional cigarette for \> half year exclusion criteria: * not pregnant and not planning pregnancy in the next 6 month bmi index \< 30 * no severe parodontal disease * no acute illness in the last 2 weeks * no chronic disease (eg.: diabetes)

Keywords: nicotine heated tobacco product blood flow cigarette
a comparison of 141w94 and indinavir in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to see if 141w94 is as safe and effective as indinavir when used with nucleoside reverse transcriptase inhibitors (nrtis) for 48 weeks. this study also examines what effect other drugs have on how the body handles 141w94.


Eligibility criteria:
inclusion criteria patients must have: * documented hiv infection. * hiv rna \>= 400 copies/ml within 14 days prior to randomized study drug administration. * no active aids-defining opportunistic infection or disease. * signed, informed consent from parent or legal guardian of patients less than 18 years of age. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * unlikely to complete the randomized dosing period. * malabsorption syndrome or other gastrointestinal dysfunction that might interfere with drug absorption or ability to take oral medications. * serious medical conditions (e.g., diabetes, cardiac dysfunction, hepatitis) that would compromise patient safety. concurrent medication: excluded: * cytotoxic chemotherapeutic agents (except local treatment for kaposi's sarcoma). * investigational treatments (treatment through treatment ind or expanded-access programs are evaluated individually). * immunomodulating agents such as systemic, high-dose corticosteroids, interleukins, or interferons. * terfenadine, astemizole, cisapride, triazolam, midazolam, and ergotamine/dihydroergotamine-containing regimens. concurrent treatment: excluded: radiation therapy (except local treatment for kaposi's sarcoma). patients with the following prior conditions are excluded: clinically relevant pancreatitis or hepatitis within the last 6 months. prior medication: excluded: * cytotoxic chemotherapeutic agents within 30 days of study drug administration (except local treatment for kaposi's sarcoma). * protease inhibitor therapy. * dose of vaccine through an investigational hiv vaccine trial within the 3 months prior to study drug administration. * immunomodulating agents such as systemic, high-dose corticosteroids, interleukins, or interferons within 30 days of study drug administration. prior treatment: excluded: radiation therapy within 30 days prior to study drug administration (except local treatment for kaposi's sarcoma). risk behavior: excluded: current alcohol or illicit drug use that may interfere with drug absorption or ability to take oral medication. required: nrti therapy at day of entry and up to screening. required: \>= 12 weeks of nrti therapy.

Keywords: hiv-1 drug therapy, combination hiv protease inhibitors indinavir rna, viral vx 478 reverse transcriptase inhibitors anti-hiv agents viral load